Bio
Degree in Medicine and Surgery, Master in Internal Ultrasound, Ph.D. in Biotechnology and Functional Bioimaging, Specialization in Cardiology, Honorary Researcher at the University “G. D'Annunzio "Chieti-Pescara; Research Fellow and Adjunct Assistant Professor at the University of Texas Medical School in Houston, TX, and the Institute of Molecular Cardiology, University of Louisville, KY; Research Scientist at the Texas Heart Institute, Houston, TX; Senior Research Scientist at the University of Pisa. Current: Associate Professor in Cardiology, University of Pisa; consultant cardiologist, University Cardiology 1, Cisanello Hospital, Pisa; qualified as Full Professor in Cardiology and Full Professor in Sciences of the health profession and applied medical technologies.

Bio
Prof. Federico Carbone, MD, PhD is an Associate Professor of Internal Medicine at the University of Genoa (Italy) and a Consultant in Internal Medicine at IRCCS Ospedale Policlinico San Martino. After completing his medical degree and residency in Internal Medicine at the University of Genoa, he earned a PhD in Cardiovascular Biology through a joint program with the University of Geneva. His research focuses on cardiometabolic medicine, with particular interests in inflammation, obesity, and atherosclerosis. Prof. Carbone serves as Deputy Editor of the European Journal of Clinical Investigation and has held multiple leadership roles within the European Society for Clinical Investigation (ESCI), including council membership, vice-presidency, and organization of the 59th Annual Scientific Meeting in 2025. His research has been supported by national and international funding bodies, including the Italian Cardiovascular Network and Swiss foundations. He has authored over 260 peer-reviewed publications (H-index: 36; total impact factor >1170; >4900 citations) and maintains active collaborations across Europe in translational cardiometabolic research.

Talk
Perspectives in Cardio-Oncology Research

Bio
Pietro Ameri, MD, PhD, is an Associate Professor in Cardiovascular Diseases and a Coordinator of the Translational and Clinical PhD program at the University of Genova, Italy. He also leads a translational research unit, the heart failure outpatient program, and the cardio-oncology service at the affiliated IRCCS San Martino Policlinic Hospital. He is currently the Secretary of the ESC Council of Cardio-Oncology, the local chairperson of the upcoming ESC 2025 Cardio-Oncology Conference, and a Member of the Scientific Committee on Basic & Translational Research of the ESC Heart Failure Association. He is the Cardiovascular Oncology Section Editor of the Journal of Thrombosis and Thrombolysis and an Associate Editor of the Journal of Cellular and Molecular Medicine. His primary interests are heart failure and cardio-oncology, especially with respect to the interplay between heart failure, cancer, and cancer treatments. Pietro Ameri's research group includes biologists, biotechnologists, and physicians and is funded by several grants. His H-index is 38.

Talk
Hidden Cardiotoxicity of Drugs: A Paradigm Shift in Cardiac Safety Testing

Bio
Prof. Dr. Péter Ferdinandy has been recognized as a Highly Cited Researcher in 2014, 2017, 2020, 2021, 2022, 2023, and 2024. He has published more than 350 papers and 6 patent families. His Hirsch index is 69. He received his MD in 1991 and his PhD in 1995 at the University of Szeged, Hungary. He received postdoctoral training at the University of Alberta, Edmonton, Canada, from 1997 to 1999. He became a registered clinical pharmacologist in 1999. He received his MBA in finance and quality management in 2004 from the Budapest University of Technology and Economics. He founded the Pharmahungary Group, a group of R&D companies (www.pharmahungary.com) that have been involved in more than 250 drug/medical device development projects since their foundation in the early 2000s. He was the president of the International Society for Heart Research, European Section, and the chair of the Working Group of Cellular Biology of the Heart of the European Society for Cardiology. Currently, he is the vice-rector for science and innovations and the director of the Department of Pharmacology and Pharmacotherapy, at Semmelweis University, Budapest (www.semmelweis.hu). He is the president of the Hungarian Society of Experimental and Clinical Pharmacology (www.huphar.org) and serves as the Editor-in-Chief of the British Journal of Pharmacology.

Talk
Doxorubicin Cardiotoxicity and Cardiac Metabolic Rewiring

Bio
Prof. Dr. Emilio Hirsh is a Professor of Cell Biology at the University of Torino Medical School and Director of the Molecular Biotechnology Center. He is an EMBO and ISHR Fellow. His research has shaped our understanding of phosphoinositide 3-kinases (PI3Ks) as multifunctional signaling and scaffolding proteins, with major contributions in cancer, inflammation, metabolic diseases, and heart failure. He has authored over 300 peer-reviewed publications with >30,000 citations and an H-index of 97 (Google Scholar). He pioneered PI3K isoform-selective targeting, generated the first PI3K- knockout mice, and contributed to the discovery of PI3Kγ inhibitors now in clinical development. He also uncovered key functions of PI3KC2α in endocytosis, primary cilia, mitosis, and cytokinesis (Nature 2013; Cancer Cell 2017; Science 2021). He is the founder of the biotech company Kither Biotech, and he holds several patents on PI3K-targeted therapies, including compounds in clinical trials. He has received funding from the Human Frontier Science Program, EU FP5-FP6, Leducq Foundation, and AIRC, and he is the recipient of the ISHR Outstanding Scientist Award. He has served on the Scientific Boards of Celzome AG, DZHK, and AIRC, and was a consultant for Merck-Serono. He has organized several international meetings (Keystone, FASEB, EMBO) and has given >100 invited lectures at major institutions and conferences worldwide. Editorial boards: Cardiovascular Research (Associate Editor), Frontiers in Oncology, Cancers, Cell Communication & Signaling, Cancers.